Detalhe da pesquisa
1.
Epidermal growth factor receptor mutation analysis in tissue and plasma from the AURA3 trial: Osimertinib versus platinum-pemetrexed for T790M mutation-positive advanced non-small cell lung cancer.
Cancer
; 126(2): 373-380, 2020 01 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-31769875
2.
VarDict: a novel and versatile variant caller for next-generation sequencing in cancer research.
Nucleic Acids Res
; 44(11): e108, 2016 06 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-27060149
3.
Longitudinal Circulating Tumor DNA Modeling to Predict Disease Progression in First-Line Mutant Epidermal Growth Factor Receptor Non-Small Cell Lung Cancer.
Clin Pharmacol Ther
; 115(2): 349-360, 2024 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-38010260
4.
Overcoming osimertinib resistance with AKT inhibition in EGFRm-driven Non-Small-Cell-Lung-Cancer with PIK3CA/PTEN alterations.
Clin Cancer Res
; 2024 Apr 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-38630555
5.
Mixed responses to targeted therapy driven by chromosomal instability through p53 dysfunction and genome doubling.
Nat Commun
; 15(1): 4871, 2024 Jun 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-38871738
6.
Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer.
Nat Commun
; 14(1): 1070, 2023 02 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-36849494
7.
Phase II Study Investigating the Safety and Efficacy of Savolitinib and Durvalumab in Metastatic Papillary Renal Cancer (CALYPSO).
J Clin Oncol
; 41(14): 2493-2502, 2023 05 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-36809050
8.
Early Clearance of Plasma Epidermal Growth Factor Receptor Mutations as a Predictor of Outcome on Osimertinib in Advanced Non-Small Cell Lung Cancer; Exploratory Analysis from AURA3 and FLAURA.
Clin Cancer Res
; 29(17): 3340-3351, 2023 Sep 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37379430
9.
Osimertinib + Savolitinib to Overcome Acquired MET-Mediated Resistance in Epidermal Growth Factor Receptor-Mutated, MET-Amplified Non-Small Cell Lung Cancer: TATTON.
Cancer Discov
; 13(1): 98-113, 2023 01 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-36264123
10.
Molecular landscape of osimertinib resistance in patients and patient-derived preclinical models.
Ther Adv Med Oncol
; 14: 17588359221079125, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35251316
11.
The landscape of therapeutic vulnerabilities in EGFR inhibitor osimertinib drug tolerant persister cells.
NPJ Precis Oncol
; 6(1): 95, 2022 Dec 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-36575215
12.
Analysis of cancer metabolism with high-throughput technologies.
BMC Bioinformatics
; 12 Suppl 10: S8, 2011 Oct 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-22166000
13.
Clinical impact of subclonal EGFR T790M mutations in advanced-stage EGFR-mutant non-small-cell lung cancers.
Nat Commun
; 12(1): 1780, 2021 03 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-33741979
14.
Promoter prediction in E. coli based on SIDD profiles and Artificial Neural Networks.
BMC Bioinformatics
; 11 Suppl 6: S17, 2010 Oct 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-20946600
15.
Exon 16-Skipping HER2 as a Novel Mechanism of Osimertinib Resistance in EGFR L858R/T790M-Positive Non-Small Cell Lung Cancer.
J Thorac Oncol
; 15(1): 50-61, 2020 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31557536
16.
Programmed Cell Death Ligand 1 Expression in Untreated EGFR Mutated Advanced NSCLC and Response to Osimertinib Versus Comparator in FLAURA.
J Thorac Oncol
; 15(1): 138-143, 2020 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31605792
17.
Mechanisms of Acquired Resistance to Savolitinib, a Selective MET Inhibitor in MET-Amplified Gastric Cancer.
JCO Precis Oncol
; 42020.
Artigo
em Inglês
| MEDLINE | ID: mdl-32923890
18.
Targeting melanoma's MCL1 bias unleashes the apoptotic potential of BRAF and ERK1/2 pathway inhibitors.
Nat Commun
; 10(1): 5167, 2019 11 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-31727888
19.
Author Correction: Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer.
Nat Commun
; 14(1): 3179, 2023 Jun 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37263992
20.
Osimertinib As First-Line Treatment of EGFR Mutation-Positive Advanced Non-Small-Cell Lung Cancer.
J Clin Oncol
; 36(9): 841-849, 2018 03 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-28841389